Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016. https://doi.org/10.1093/annonc/mdw235.
Article
PubMed
PubMed Central
Google Scholar
Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016. https://doi.org/10.1093/annonc/mdw324.
Article
PubMed
Google Scholar
Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011. https://doi.org/10.1007/s00259-011-1812-2.
Article
PubMed
Google Scholar
Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018. https://doi.org/10.1016/j.jhep.2018.03.019.
Article
PubMed
Google Scholar
Dufour JF, Greten TF, Raymond E, et al. Clinical practice guidelines EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma european organisation for research and treatment of cancer. J Hepatol. 2012. https://doi.org/10.1016/j.jhep.2011.12.001.
Article
PubMed
Google Scholar
Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) Colon Cancer, Version 4.2020. NCCN website. 15 June 2020. Accessed 24 August 2020. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
Benson AB, D’Angelica MI, Abbott DE, et al. NCCN Clinical practice guidelines in oncology (NCCN Guidelines ®) Hepatobiliary Cancers, Version 5.2020. NCCN website. 4 August 2020. Accessed 24 August 2020. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf
Sangro B, Salem R. Transarterial chemoembolization and radioembolization. Semin Liver Dis. 2014. https://doi.org/10.1055/s-0034-1394142.
Article
PubMed
Google Scholar
Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010. https://doi.org/10.1053/j.gastro.2009.09.006.
Article
PubMed
PubMed Central
Google Scholar
Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013. https://doi.org/10.1002/hep.26014.
Article
PubMed
PubMed Central
Google Scholar
Hilgard P, Hamami M, El Fouly A, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010. https://doi.org/10.1002/hep.23944.
Article
PubMed
Google Scholar
Sangro B, Carpanese L, Cianni R, et al. Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011. https://doi.org/10.1002/hep.24451.
Article
PubMed
Google Scholar
Mancini R, Carpanese L, Sciuto R, et al. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90Yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: Preliminary results on toxicity and response rates. In Vivo (Brooklyn). 2006.
Sofocleous CT, Garcia AR, Pandit-Taskar N, et al. Phase i trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014. https://doi.org/10.1016/j.clcc.2013.11.010.
Article
PubMed
Google Scholar
Gulec SA, Pennington K, Wheeler J, et al. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (Chemo-SIRT) for colorectal cancer liver metastases: An in vivo double-arm-controlled phase II trial. Am J Clin Oncol Cancer Clin Trials. 2013. https://doi.org/10.1097/COC.0b013e3182546c50.
Article
Google Scholar
Martin LK, Cucci A, Wei L, et al. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin Colorectal Cancer. 2012. https://doi.org/10.1016/j.clcc.2011.12.002.
Article
PubMed
PubMed Central
Google Scholar
Hendlisz A, Van Den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010. https://doi.org/10.1200/JCO.2010.28.5643.
Article
PubMed
Google Scholar
Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017. https://doi.org/10.1016/S1470-2045(17)30683-6.
Article
PubMed
Google Scholar
Wasan HS, Gibbs P, Sharma N, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017. https://doi.org/10.1016/S1470-2045(17)30457-6.
Article
PubMed
PubMed Central
Google Scholar
Sharma RA, Wasan HS, Van Hazel GA, et al. Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. J Clin Oncol. 2018. https://doi.org/10.1200/jco.2017.35.15_suppl.3507.
Article
PubMed
PubMed Central
Google Scholar
Chauhan N, Mulcahy MF, Salem R, et al. Therasphere yttrium-90 glass microspheres combined with chemotherapy versus chemotherapy alone in second-line treatment of patients with metastatic colorectal carcinoma of the liver: Protocol for the EPOCH phase 3 randomized clinical trial. J Med Internet Res. 2019. https://doi.org/10.2196/11545.
Article
Google Scholar
Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2017.76.0892.
Article
PubMed
PubMed Central
Google Scholar
Saxena A, Meteling B, Kapoor J, Golani S, Morris DL, Bester L. Is Yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol. 2015. https://doi.org/10.1245/s10434-014-4164-x.
Article
PubMed
Google Scholar
Kennedy AS, Ball D, Cohen SJ, et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for 90Y resin microspheres. J Gastrointest Oncol. 2015. https://doi.org/10.3978/j.issn.2078-6891.2014.109.
Article
PubMed
PubMed Central
Google Scholar
Rognoni C, Ciani O, Sommariva S, et al. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: Systematic review and meta-analyses. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.11644.
Article
PubMed
PubMed Central
Google Scholar
Levillain H, Duran Derijckere I, Ameye L, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04427-z.
Article
PubMed
Google Scholar
Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08486-7.
Article
PubMed
Google Scholar
Cucchetti A, Cappelli A, Mosconi C, et al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: a meta-regression study. Liver Int. 2017. https://doi.org/10.1111/liv.13382.
Article
PubMed
Google Scholar
Sangro B, Maini CL, Ettorre GM, et al. Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-3968-5.
Article
PubMed
PubMed Central
Google Scholar
Bargellini I, Mosconi C, Pizzi G, et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol. 2020. https://doi.org/10.1007/s00270-020-02569-4.
Article
PubMed
PubMed Central
Google Scholar
Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. HepatoBiliary Surg Nutr. 2018. https://doi.org/10.21037/hbsn.2018.10.06
White J, Carolan-Rees G, Dale M, et al. Analysis of a national programme for selective internal radiation therapy for colorectal cancer liver metastases. Clin Oncol. 2019;31(1):58–66. https://doi.org/10.1016/j.clon.2018.09.002.
CAS
Article
Google Scholar
White J, Carolan-Rees G, Dale M, et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective. Observational Study. J Vasc Interv Radiol. 2019;30(8):1185–92. https://doi.org/10.1016/j.jvir.2019.03.018.
Article
PubMed
Google Scholar
Kuei A, Saab S, Cho SK, Kee ST, Lee EW. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World J Gastroenterol. 2015. https://doi.org/10.3748/wjg.v21.i27.8271.
Article
PubMed
PubMed Central
Google Scholar
Barbier CE, Garske-Román U, Sandström M, Nyman R, Granberg D. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2016. https://doi.org/10.1007/s00259-015-3264-6.
Article
PubMed
Google Scholar
Puippe G, Pfammatter T, Schaefer N. Arterial therapies of non-colorectal liver metastases. Visz Gastrointest Med Surg. 2015;31(6):414–22. https://doi.org/10.1159/000441689.
Article
Google Scholar
Helmberger T, Arnold D, Bilbao JI, et al. Clinical application of radioembolization in hepatic malignancies: Protocol for a prospective multicenter observational study. J Med Internet Res. 2020. https://doi.org/10.2196/16296.
Article
Google Scholar
Kurilova I, Beets-Tan RGH, Flynn J, et al. Factors affecting oncologic outcomes of 90Y radioembolization of heavily pre-treated patients with colon cancer liver metastases. Clin Colorectal Cancer. 2019. https://doi.org/10.1016/j.clcc.2018.08.004.
Article
PubMed
Google Scholar
Damm R, Seidensticker R, Ulrich G, et al. Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. BMC Cancer. 2016. https://doi.org/10.1186/s12885-016-2549-x.
Article
PubMed
PubMed Central
Google Scholar
Sofocleous CT, Violari EG, Sotirchos VS, et al. Radioembolization as a salvage therapy for heavily pretreated patients with colorectal cancer liver metastases: factors that affect outcomes. Clin Colorectal Cancer. 2015. https://doi.org/10.1016/j.clcc.2015.06.003.
Article
PubMed
PubMed Central
Google Scholar
Barat M, Cottereau A-S, Kedra A, et al. The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J Clin Med. 2020. https://doi.org/10.3390/jcm9072302.
Article
PubMed
PubMed Central
Google Scholar
Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol. 2018. https://doi.org/10.1016/j.ejrad.2018.01.012.
Article
PubMed
Google Scholar
Zuckerman DA, Kennard RF, Roy A, Parikh PJ, Weiner AA. Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors—a single-institution experience. J Gastrointest Oncol. 2019. https://doi.org/10.21037/jgo.2018.10.05.
Article
PubMed
PubMed Central
Google Scholar
Bale R, Putzer D, Schullian P. Local treatment of breast cancer liver metastasis. Cancers (Basel). 2019. https://doi.org/10.3390/cancers11091341.
Article
PubMed
PubMed Central
Google Scholar
Gordon AC, Gradishar WJ, Kaklamani VG, et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol. 2014. https://doi.org/10.1016/j.jvir.2014.07.007.
Article
PubMed
PubMed Central
Google Scholar
Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008. https://doi.org/10.1016/j.jvir.2008.01.009.
Article
PubMed
Google Scholar
Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB. 2020. https://doi.org/10.1016/j.hpb.2019.11.002.
Article
PubMed
Google Scholar
Gibbs P, Do C, Lipton L, et al. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer. 2015. https://doi.org/10.1186/s12885-015-1822-8.
Article
PubMed
PubMed Central
Google Scholar
Michl M, Haug AR, Jakobs TF, et al. Radioembolization with yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: Efficacy, safety and prognostic factors. Oncol. 2014. https://doi.org/10.1159/000355821.
Article
Google Scholar
Tulokas S, Mäenpää H, Peltola E, et al. Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience. Acta Oncol (Madr). 2018. https://doi.org/10.1080/0284186X.2018.1465587.
Article
Google Scholar
Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020. https://doi.org/10.1001/jamaoncol.2019.3702.
Article
Google Scholar
Feretis M, Solodkyy A. Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: a systematic review. World J Gastrointest Oncol. 2020. https://doi.org/10.4251/wjgo.v12.i2.228.
Article
PubMed
PubMed Central
Google Scholar
Xing M, Prajapati HJ, Dhanasekaran R, et al. Selective internal yttrium-90 radioembolization therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy: Safety and efficacy cohort study. Am J Clin Oncol Cancer Clin Trials. 2017. https://doi.org/10.1097/COC.0000000000000109.
Article
Google Scholar
Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015. https://doi.org/10.1016/j.ejso.2014.09.007.
Article
PubMed
PubMed Central
Google Scholar
Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015. https://doi.org/10.1002/jso.23781.
Article
PubMed
Google Scholar
Ricke J, Sangro B, Amthauer H, et al. The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the soramic trial palliative cohort. J Hepatol. 2018. https://doi.org/10.1016/s0168-8278(18)30424-0.
Article
Google Scholar
Abdallah MA, Wongjarupong N, Hassan MA, et al. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Rev Gastroenterol Hepatol. 2020. https://doi.org/10.1080/17474124.2020.1777856.
Article
PubMed
Google Scholar
Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1000-patient 15-year experience. Hepatology. 2018. https://doi.org/10.1002/hep.29691.
Article
PubMed
Google Scholar
Abouchaleh N, Gabr A, Ali R, et al. 90 Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: Long-term outcomes in a 185-patient cohort. J Nucl Med. 2018. https://doi.org/10.2967/jnumed.117.199752.
Article
PubMed
Google Scholar
Reimer P, Virarkar MK, Binnenhei M, Justinger M, Schön MR, Tatsch K. Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: results in therapy-naïve patients. Cardiovasc Intervent Radiol. 2018. https://doi.org/10.1007/s00270-017-1871-2.
Article
PubMed
Google Scholar
Köhler M, Harders F, Lohöfer F, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. 2019;9(1):56. https://doi.org/10.3390/jcm9010056.
CAS
Article
PubMed Central
Google Scholar
Hickey R, Lewandowski RJ, Prudhomme T, et al. 90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med. 2016. https://doi.org/10.2967/jnumed.115.166082.
Article
PubMed
Google Scholar
Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008. https://doi.org/10.1002/hep.21980.
Article
PubMed
Google Scholar
Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012. https://doi.org/10.1016/j.jhep.2011.07.012.
Article
PubMed
Google Scholar
Lahti SJ, Xing M, Zhang D, Lee JJ, Magnetta MJ, Kim HS. KRAS status as an independent prognostic factor for survival after yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastases. J Vasc Interv Radiol. 2015. https://doi.org/10.1016/j.jvir.2015.05.032.
Article
PubMed
Google Scholar
Ziv E, Bergen M, Yarmohammadi H, et al. PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.15278.
Article
PubMed
PubMed Central
Google Scholar
van den Hoven A, Rosenbaum C, Elias S, et al. Insights into the dose-response relationship of hepatic radioembolization with resin yttrium-90 microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Vasc Interv Radiol. 2016. https://doi.org/10.1016/j.jvir.2015.12.031.
Article
Google Scholar
Hermann A-L, Dieudonné A, Ronot M, et al. Relationship of tumor radiation–absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90 Y in the SARAH study. Radiology. 2020. https://doi.org/10.1148/radiol.2020191606.
Article
PubMed
Google Scholar
Sofocleous CT, Vasiniotis Kamarinos N. Tumor-absolbed dose: the missing link in radioembolization. Radiology. 2020. https://doi.org/10.1148/radiol.2020202354.
Article
PubMed
Google Scholar
Adam A, De Baère T, Bilbao JI, et al. Standards of quality assurance in interventional oncology, First Edition. CIRSE–Cardiovascular and Interventional Radiological Society of Europe. 2018. ISBN 978-3-9502501-5-2